What is Advicenne?
Advicenne is a specialty pharmaceutical firm dedicated to the development of innovative treatments for rare renal diseases, such as distal renal tubular acidosis (dRTA) and cystinuria, as well as neurological conditions. With a decade of experience, the company's primary focus is on improving the quality of life for patients, particularly children, who have limited therapeutic options. Their flagship product, Sibnayal, has achieved regulatory approval in Europe and the UK, demonstrating Advicenne's capability in bringing novel therapies from development to market. Headquartered in Paris and publicly listed on Euronext Growth, Advicenne is committed to tackling high unmet medical needs for both pediatric and adult populations.
How much funding has Advicenne raised?
Advicenne has raised a total of $53.5M across 2 funding rounds:
Unspecified
$17.2M
Stock Offering
$36.4M
Unspecified (2017): $17.2M with participation from Bpifrance and InnoBio and iXO Private Equity
Stock Issuance/Offering (2017): $36.4M, investors not publicly disclosed
Key Investors in Advicenne
Bpifrance
Bpifrance is a French public investment bank that supports companies at every stage of their development, providing credit, guarantees, and equity. They are active in financing innovation projects and international expansion.
iXO Private Equity
iXO Private Equity is an investment firm that provides capital for companies. Their involvement suggests a focus on supporting growth and development within their portfolio companies.
What's next for Advicenne?
With the recent major strategic investment and substantial total capital raised, Advicenne is well-positioned to accelerate its growth trajectory. The company is expected to leverage this financing to further expand its product pipeline, potentially through continued research and development or strategic acquisitions. Advicenne's focus on orphan diseases and pediatric therapeutics, coupled with regulatory approvals for Sibnayal, suggests a strategic emphasis on niche markets with high therapeutic impact. Future endeavors will likely involve scaling commercial operations, expanding market reach beyond Europe and the UK, and continuing to address critical unmet medical needs in its specialized therapeutic areas.
See full Advicenne company page
